Amphastar Pharmaceuticals (AMPH) Research & Development (2016 - 2025)
Historic Research & Development for Amphastar Pharmaceuticals (AMPH) over the last 13 years, with Q3 2025 value amounting to $22.4 million.
- Amphastar Pharmaceuticals' Research & Development rose 605.87% to $22.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $80.7 million, marking a year-over-year increase of 588.13%. This contributed to the annual value of $73.9 million for FY2024, which is 23.46% up from last year.
- As of Q3 2025, Amphastar Pharmaceuticals' Research & Development stood at $22.4 million, which was up 605.87% from $20.1 million recorded in Q2 2025.
- Amphastar Pharmaceuticals' 5-year Research & Development high stood at $22.8 million for Q2 2022, and its period low was $10.8 million during Q3 2021.
- Its 5-year average for Research & Development is $18.2 million, with a median of $18.1 million in 2021.
- In the last 5 years, Amphastar Pharmaceuticals' Research & Development tumbled by 3902.18% in 2021 and then skyrocketed by 7207.92% in 2022.
- Quarter analysis of 5 years shows Amphastar Pharmaceuticals' Research & Development stood at $17.3 million in 2021, then fell by 0.29% to $17.2 million in 2022, then rose by 18.47% to $20.4 million in 2023, then dropped by 11.15% to $18.1 million in 2024, then grew by 23.22% to $22.4 million in 2025.
- Its Research & Development stands at $22.4 million for Q3 2025, versus $20.1 million for Q2 2025 and $20.1 million for Q1 2025.